Entos Pharmaceuticals Inc.

Canada

Back to Profile

1-37 of 37 for Entos Pharmaceuticals Inc. Sort by
Query
Aggregations
IP Type
        Patent 21
        Trademark 16
Jurisdiction
        United States 17
        Canada 10
        World 7
        Europe 3
Date
2024 December 2
2024 November 1
2024 5
2023 9
2022 11
See more
IPC Class
A61P 35/04 - Antineoplastic agents specific for metastasis 9
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides 8
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides 7
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides 6
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant 5
See more
NICE Class
42 - Scientific, technological and industrial services, research and design 14
05 - Pharmaceutical, veterinary and sanitary products 12
40 - Treatment of materials; recycling, air and water treatment, 10
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 10
01 - Chemical and biological materials for industrial, scientific and agricultural use 8
See more
Status
Pending 21
Registered / In Force 16

1.

SARS COV-2 VACCINES, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Application Number 18678619
Status Pending
Filing Date 2024-05-30
First Publication Date 2024-12-05
Owner
  • Aegis Life, Inc. (USA)
  • Entos Pharmaceuticals, Inc. (Canada)
Inventor
  • Lewis, John
  • Raturi, Arun
  • Duncan, Roy
  • Wee, Ping
  • Bhandari, Prakash
  • Thompson, Thornton
  • Sevy, Alex

Abstract

The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

IPC Classes  ?

2.

SARS COV-2 VACCINES, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Application Number US2024031700
Publication Number 2024/249651
Status In Force
Filing Date 2024-05-30
Publication Date 2024-12-05
Owner
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventor
  • Lewis, John
  • Raturi, Arun
  • Duncan, Roy
  • Wee, Ping
  • Bhandari, Prakash
  • Thompson, Thornton
  • Sevy, Alex

Abstract

The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

3.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Application Number 18613605
Status Pending
Filing Date 2024-03-22
First Publication Date 2024-11-14
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John David
  • Raturi, Arun

Abstract

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

IPC Classes  ?

  • A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

4.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Application Number 18029823
Status Pending
Filing Date 2021-10-01
First Publication Date 2024-06-13
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John David
  • Raturi, Arun

Abstract

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

IPC Classes  ?

  • A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

5.

DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT

      
Application Number 18303407
Status Pending
Filing Date 2023-04-19
First Publication Date 2024-03-21
Owner
  • Aegis Life, Inc. (USA)
  • Entos Pharmaceuticals, Inc. (Canada)
Inventor
  • Sevy, Alexander
  • Abel, Brian
  • Jiang, Hong
  • Raturi, Arun
  • Thompson, Thornton
  • Lewis, John
  • Wee, Ping

Abstract

The present disclosure relates to systems for the expression of antibodies or antigen binding fragments in a subject, as well as methods of treatments of diseases therewith.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61P 35/00 - Antineoplastic agents

6.

DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT

      
Application Number US2023019104
Publication Number 2023/205239
Status In Force
Filing Date 2023-04-19
Publication Date 2023-10-26
Owner
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventor
  • Sevy, Alexander
  • Abel, Brian
  • Jiang, Hong
  • Raturi, Arun
  • Thompson, Thornton
  • Lewis, John
  • Wee, Ping

Abstract

The present disclosure relates to systems for the expression of antibodies or antigen binding fragments in a subject, as well as methods of treatments of diseases therewith.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • A61P 35/00 - Antineoplastic agents
  • A61P 31/12 - Antivirals

7.

RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF

      
Application Number 17933193
Status Pending
Filing Date 2022-09-19
First Publication Date 2023-06-22
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Duncan, Roy
  • Clancy, Eileen Kathryn
  • Lewis, John
  • De Antueno, Roberto Justo
  • Nesbitt, Rae-Lynn

Abstract

Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.

IPC Classes  ?

  • C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
  • A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

8.

SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Document Number 03238159
Status Pending
Filing Date 2022-11-29
Open to Public Date 2023-06-01
Owner
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventor
  • Jiang, Hong
  • Lewis, John
  • Raturi, Arun
  • Thompson, Thornton

Abstract

The present disclosure relates to vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use. The vaccine formulations further comprise DNA vectors encoding SARS-Cov-2 spike protein variants comprising single amino acid substitutions and polynucleotides which encode an adjuvant, further wherein the vaccine is formulated with a proteolipid vesicle or fusogenic membrane protein.

IPC Classes  ?

  • A61K 39/12 - Viral antigens
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
  • A61P 31/14 - Antivirals for RNA viruses
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

9.

SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Application Number US2022051178
Publication Number 2023/097102
Status In Force
Filing Date 2022-11-29
Publication Date 2023-06-01
Owner
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventor
  • Jiang, Hong
  • Lewis, John
  • Raturi, Arun
  • Thompson, Thornton

Abstract

The present disclosure relates to vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use. The vaccine formulations further comprise DNA vectors encoding SARS-Cov-2 spike protein variants comprising single amino acid substitutions and polynucleotides which encode an adjuvant, further wherein the vaccine is formulated with a proteolipid vesicle or fusogenic membrane protein.

IPC Classes  ?

  • A61K 39/12 - Viral antigens
  • A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61P 31/14 - Antivirals for RNA viruses
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

10.

PLV

      
Application Number 018875766
Status Registered
Filing Date 2023-05-16
Registration Date 2023-10-04
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock); Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases; pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers); vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis); pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery agents that facilitate the intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents. Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies. Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates. Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes.

11.

FUSOGENIX

      
Application Number 018875828
Status Registered
Filing Date 2023-05-16
Registration Date 2023-10-04
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock); Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases; pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers); vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis); pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery agents that facilitate the intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents. Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies. Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates. Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes.

12.

PLV

      
Serial Number 97939663
Status Pending
Filing Date 2023-05-16
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the nature of pneumonia, kidneys in the nature of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery system, comprising FAST proteins for intracellular delivery of therapeutic agents; drug delivery system, comprising naturally occurring, engineered and FAST proteins fused to antibodies, polypeptide sequences and targeting ligands, namely, Alpha-V/Beta3, RGD, EGFL7, PC3, Hepsin, Protease cleaved collagen IV and Plectin, for intracellular delivery of therapeutic agents; drug delivery system, comprising charged, ionizable and cationic lipids to neutralize nucleic acid cargo(es) and overall particle charge for intracellular delivery of therapeutic agents; drug delivery system, comprising helper lipids to mediate particle morphology, structure, fluidity and FAST protein stabilization for intracellular delivery of therapeutic agents; drug delivery system, comprising conjugated lipids, namely, pegylated lipids for stability and size, and cargoes, namely, DNA, plasmid DNA, circular DNA, single stranded DNA, RNA, mRNA, siRNA, miRNA, shRNA, tRNA, protein, peptides, small molecules, and combinations thereof for intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes

13.

FUSOGENIX

      
Serial Number 97939674
Status Pending
Filing Date 2023-05-16
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the nature of pneumonia, kidneys in the nature of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery system, comprising FAST proteins for intracellular delivery of therapeutic agents; drug delivery system, comprising naturally occurring, engineered and FAST proteins fused to antibodies, polypeptide sequences and targeting ligands, namely, Alpha-V/Beta3, RGD, EGFL7, PC3, Hepsin, Protease cleaved collagen IV and Plectin, for intracellular delivery of therapeutic agents; drug delivery system, comprising charged, ionizable and cationic lipids to neutralize nucleic acid cargo(es) and overall particle charge for intracellular delivery of therapeutic agents; drug delivery system, comprising helper lipids to mediate particle morphology, structure, fluidity and FAST protein stabilization for intracellular delivery of therapeutic agents; drug delivery system, comprising conjugated lipids, namely, pegylated lipids for stability and size, and cargoes, namely, DNA, plasmid DNA, circular DNA, single stranded DNA, RNA, mRNA, siRNA, miRNA, shRNA, tRNA, protein, peptides, small molecules, and combinations thereof for intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes

14.

COMPOSITIONS AND METHODS FOR LIVER-SPECIFIC EXPRESSION OF FOLLISTATIN

      
Application Number US2022045468
Publication Number 2023/056070
Status In Force
Filing Date 2022-09-30
Publication Date 2023-04-06
Owner
  • OISIN BIOTECHNOLOGIES, INC. (USA)
  • ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Scholz, Matthew Rein
  • Lewis, John David

Abstract

Provided herein are expression constructs for liver-specific expression of transgenes, such as follistatin. Also provided are delivery vectors for the expression constructs, and methods of expressing follistatin in a subject to increase muscular strength and mass, or treat a condition.

IPC Classes  ?

  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

15.

FUSOGENIX

      
Application Number 222386100
Status Pending
Filing Date 2022-11-23
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

16.

PLV

      
Application Number 222386200
Status Pending
Filing Date 2022-11-23
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

17.

ENTOS

      
Serial Number 97978410
Status Registered
Filing Date 2022-09-14
Registration Date 2024-11-19
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purpose

18.

ENTOS

      
Serial Number 97590573
Status Pending
Filing Date 2022-09-14
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments

Goods & Services

Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems, namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely, Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry Nucleic acid sequencers for scientific purposes Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

19.

ENTOS

      
Serial Number 97590585
Status Pending
Filing Date 2022-09-14
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments

Goods & Services

Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry Nucleic acid sequencers for scientific purposes Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

20.

ENTOS

      
Serial Number 97977591
Status Registered
Filing Date 2022-09-14
Registration Date 2024-07-16
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely, gene therapy services; medical analysis services, namely, RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes

21.

ENTOS

      
Application Number 220893000
Status Pending
Filing Date 2022-09-09
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for use in the biotechnological industry; (2) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (3) Nucleic acid sequencers for scientific purposes; (4) Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection; (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

22.

ENTOS

      
Application Number 220893100
Status Pending
Filing Date 2022-09-09
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

(1) Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for use in the biotechnological industry; (2) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (3) Nucleic acid sequencers for scientific purposes; (4) Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection; (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

23.

METHODS FOR DIAGNOSING AND TREATING METASTATIC CANCER

      
Application Number 17558705
Status Pending
Filing Date 2021-12-22
First Publication Date 2022-04-14
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abstract

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

24.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Document Number 03194553
Status Pending
Filing Date 2021-10-01
Open to Public Date 2022-04-07
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John David
  • Raturi, Arun

Abstract

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

IPC Classes  ?

  • A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • C07C 69/025 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen esterified with unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
  • C07C 217/28 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
  • C07C 219/08 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
  • C07F 9/10 - Phosphatides, e.g. lecithin
  • C07K 17/02 - Peptides being immobilised on, or in, an organic carrier

25.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Application Number CA2021051377
Publication Number 2022/067446
Status In Force
Filing Date 2021-10-01
Publication Date 2022-04-07
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John David
  • Raturi, Arun

Abstract

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

IPC Classes  ?

  • A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 9/51 - Nanocapsules
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
  • C07C 217/28 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
  • C07C 219/08 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
  • C07C 69/025 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen esterified with unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
  • C07F 9/10 - Phosphatides, e.g. lecithin
  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
  • C07K 19/00 - Hybrid peptides
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

26.

ENTOS

      
Application Number 018605861
Status Registered
Filing Date 2021-11-22
Registration Date 2022-05-18
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 09 - Scientific and electric apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

chemical and biological agents for scientific and research use. pharmaceuticals; pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; chemical preparations and biological preparations for the treatment of diseases and disorders; veterinary preparations, namely veterinary drugs. Downloadable computer software; downloadable software applications; downloadable software for optimizing the development and discovering of new and existing molecules, drugs, and batteries, all for use in the field of computer science, chemistry, biochemistry, physics, chemical engineering, and biology; downloadable software applications for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products; customized downloadable computer software using artificial intelligence and machine learning to provide bespoke digital simulations in the fields of chemistry, physics, biology, biochemistry, computer science, and chemical engineering. Providing temporary use of non-downloadable software; software as a service [SaaS]; platform as a service [PaaS]; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (saas) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (paas) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products.

27.

ENTOS

      
Application Number 214212000
Status Pending
Filing Date 2021-10-21
Owner Entos Pharmaceuticals Inc. (Canada)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 09 - Scientific and electric apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

(1) Chemical and biological agents for scientific and research use (2) Pharmaceuticals; pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders and therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; chemical preparations and biological preparations for the treatment of diseases and disorders; veterinary preparations (3) Downloadable software for optimizing the development and discovering of new and existing molecules, drugs, and batteries, all for use in the field of computer science, chemistry, biochemistry, physics, chemical engineering, and biology; downloadable software applications for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products; customized downloadable computer software using artificial intelligence and machine learning to provide bespoke digital simulations in the fields of chemistry, physics, biology, biochemistry, computer science, and chemical engineering (1) Research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (saas) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (paas) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

28.

ENTOS

      
Serial Number 90894329
Status Registered
Filing Date 2021-08-20
Registration Date 2023-08-29
Owner ENTOS PHARMACEUTICALS INC. (Canada)
NICE Classes  ? 42 - Scientific, technological and industrial services, research and design

Goods & Services

research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (saas) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (paas) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

29.

ENTOS

      
Serial Number 88930350
Status Registered
Filing Date 2020-05-22
Registration Date 2021-07-13
Owner ENTOS PHARMACEUTICALS INC. (Canada)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Downloadable software for optimizing the development and discovering of new and existing molecules, drugs, and batteries, all for use in the field of computer science, chemistry, biochemistry, physics, chemical engineering, and biology; downloadable software applications for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products; customized downloadable computer software using artificial intelligence and machine learning to provide bespoke digital simulations in the fields of chemistry, physics, biology, biochemistry, computer science, and chemical engineering Scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

30.

RECOMBINANT ONCOLYTIC VIRUSES FOR TREATMENT OF METASTATIC CANCERS

      
Application Number 16626019
Status Pending
Filing Date 2018-06-22
First Publication Date 2020-04-23
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Duncan, Roy
  • Pan, Chungen

Abstract

Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.

IPC Classes  ?

  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
  • A61K 35/765 - ReovirusRotavirus
  • A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
  • A61P 35/04 - Antineoplastic agents specific for metastasis

31.

Methods for diagnosing and treating metastatic cancer

      
Application Number 16309800
Grant Number 11236331
Status In Force
Filing Date 2017-06-14
First Publication Date 2019-06-13
Grant Date 2022-02-01
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abstract

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, Cl4orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

32.

RECOMBINANT ONCOLYTIC VIRUSES FOR TREATMENT OF METASTATIC CANCERS

      
Application Number CA2018050766
Publication Number 2018/232523
Status In Force
Filing Date 2018-06-22
Publication Date 2018-12-27
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Duncan, Roy
  • Pan, Chungen

Abstract

Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane (FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.

IPC Classes  ?

  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • A61K 35/76 - VirusesSubviral particlesBacteriophages
  • A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • C07K 14/14 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
  • C12N 15/46 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
  • C12N 15/86 - Viral vectors

33.

RECOMBINANT ONCOLYTIC VIRUSES FOR TREATMENT OF METASTATIC CANCERS

      
Document Number 03068340
Status Pending
Filing Date 2018-06-22
Open to Public Date 2018-12-27
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Duncan, Roy
  • Pan, Chungen

Abstract

Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane (FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.

IPC Classes  ?

  • C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
  • A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
  • A61K 35/76 - VirusesSubviral particlesBacteriophages
  • A61P 35/00 - Antineoplastic agents
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • C07K 14/14 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
  • C12N 15/46 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
  • C12N 15/86 - Viral vectors

34.

METHODS FOR DIAGNOSING AND TREATING METASTATIC CANCER

      
Application Number CA2017050729
Publication Number 2017/214726
Status In Force
Filing Date 2017-06-14
Publication Date 2017-12-21
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abstract

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

IPC Classes  ?

  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

35.

METHODS FOR DIAGNOSING AND TREATING METASTATIC CANCER

      
Document Number 03027430
Status Pending
Filing Date 2017-06-14
Open to Public Date 2017-12-21
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abstract

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

IPC Classes  ?

  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

36.

Recombinant polypeptides for membrane fusion and uses thereof

      
Application Number 13877101
Grant Number 10227386
Status In Force
Filing Date 2011-09-29
First Publication Date 2014-10-23
Grant Date 2019-03-12
Owner Entos Pharmaceuticals Inc. (Canada)
Inventor
  • Duncan, Roy
  • Clancy, Eileen Kathryn
  • Lewis, John
  • De Antueno, Roberto Justo
  • Nesbitt, Rae-Lynn

Abstract

Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.

IPC Classes  ?

  • C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
  • C07K 14/01 - DNA viruses
  • A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof

37.

RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF

      
Document Number 02813300
Status Pending
Filing Date 2011-09-29
Open to Public Date 2012-04-05
Owner ENTOS PHARMACEUTICALS INC. (Canada)
Inventor
  • Duncan, Roy
  • Clancy, Eileen Kathryn
  • Lewis, John
  • De Antueno, Roberto Justo
  • Nesbitt, Rae-Lynn

Abstract

Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.

IPC Classes  ?

  • C07K 14/14 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
  • C07K 17/04 - Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
  • C12N 15/02 - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
  • C12N 15/46 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
  • C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle